Monte Rosa Therapeutics (GLUE) Assets (2020 - 2026)
Monte Rosa Therapeutics (GLUE) posted quarterly Assets of $736.4 million for Q1 2026, up 87.29% year-over-year from $393.2 million in Q1 2025, and up 64.14% quarter-over-quarter from $448.7 million in Q4 2025.
Monte Rosa Therapeutics (GLUE) Assets (2020 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Assets history runs 7 years deep, the most recent figure standing at $736.4 million for Q1 2026.
- In Q1 2026, Assets rose 87.29% year-over-year to $736.4 million; the TTM figure through Mar 2026 stood at $736.4 million (up 87.29% YoY), while the FY2025 annual figure was $448.7 million, up 2.26% from the prior year.
- Assets for Q1 2026 stood at $736.4 million, up from $448.7 million in the prior quarter.
- The five-year high for Assets was $736.4 million in Q1 2026, with the low at $252.1 million in Q3 2023.
- The 5-year median for Assets is $346.0 million (2022), against an average of $371.6 million.
- The sharpest annual moves came in 2023 and 2026: Assets fell 29.5% in 2023, then surged 87.29% in 2026.
- Monte Rosa Therapeutics' Assets stood at $342.4 million in 2022, then dropped by 11.28% to $303.8 million in 2023, then soared by 44.44% to $438.7 million in 2024, then climbed by 2.26% to $448.7 million in 2025, then soared by 64.14% to $736.4 million in 2026.
- Business Quant data shows GLUE's Assets at $736.4 million in Q1 2026, $448.7 million in Q4 2025, and $459.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Monte Rosa Therapeutics | 1.32 Bn | 688.11 Mn | - | 691.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 691.16 Mn |
| Mar 31, 2026 | 736.43 Mn |
| Dec 31, 2025 | 448.66 Mn |
| Sep 30, 2025 | 459.84 Mn |
| Jun 30, 2025 | 359.59 Mn |
| Mar 31, 2025 | 393.20 Mn |
| Dec 31, 2024 | 438.73 Mn |
| Sep 30, 2024 | 315.08 Mn |
| Jun 30, 2024 | 344.11 Mn |
| Mar 31, 2024 | 266.75 Mn |
| Dec 31, 2023 | 303.76 Mn |
| Sep 30, 2023 | 252.10 Mn |
| Jun 30, 2023 | 278.62 Mn |
| Mar 31, 2023 | 309.03 Mn |
| Dec 31, 2022 | 342.39 Mn |
| Sep 30, 2022 | 357.60 Mn |
| Jun 30, 2022 | 365.06 Mn |
| Mar 31, 2022 | 346.01 Mn |
| Dec 31, 2021 | 366.33 Mn |
| Sep 30, 2021 | 384.05 Mn |